Which has higher earnings & valuation, ASMB or TRLV?

Trulieve Cannabis has lower revenue, but higher earnings than Assembly Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Assembly Biosciences $74.85M 7.19 -$6.12M $1.02 33.18 Trulieve Cannabis N/A N/A N/A N/A N/A

Does the media favor ASMB or TRLV?

In the previous week, Assembly Biosciences had 10 more articles in the media than Trulieve Cannabis. MarketBeat recorded 12 mentions for Assembly Biosciences and 2 mentions for Trulieve Cannabis. Assembly Biosciences' average media sentiment score of 0.63 beat Trulieve Cannabis' score of 0.00 indicating that Assembly Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Assembly Biosciences 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Trulieve Cannabis 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ASMB or CMPS?

In the previous week, Assembly Biosciences had 8 more articles in the media than Compass Pathways. MarketBeat recorded 12 mentions for Assembly Biosciences and 4 mentions for Compass Pathways. Assembly Biosciences' average media sentiment score of 0.63 beat Compass Pathways' score of 0.26 indicating that Assembly Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Assembly Biosciences 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Compass Pathways 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer PRGO or ASMB?

In the previous week, Assembly Biosciences had 9 more articles in the media than Perrigo. MarketBeat recorded 12 mentions for Assembly Biosciences and 3 mentions for Perrigo. Assembly Biosciences' average media sentiment score of 0.63 beat Perrigo's score of 0.13 indicating that Assembly Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Perrigo 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Assembly Biosciences 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor ASMB or ANIP?

In the previous week, ANI Pharmaceuticals had 3 more articles in the media than Assembly Biosciences. MarketBeat recorded 15 mentions for ANI Pharmaceuticals and 12 mentions for Assembly Biosciences. Assembly Biosciences' average media sentiment score of 0.63 beat ANI Pharmaceuticals' score of 0.58 indicating that Assembly Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Assembly Biosciences 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive ANI Pharmaceuticals 6 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer AVLN or ASMB?

In the previous week, Assembly Biosciences had 5 more articles in the media than Avalyn Pharma. MarketBeat recorded 12 mentions for Assembly Biosciences and 7 mentions for Avalyn Pharma. Assembly Biosciences' average media sentiment score of 0.63 beat Avalyn Pharma's score of 0.36 indicating that Assembly Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalyn Pharma 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Assembly Biosciences 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Assembly Biosciences (ASMB) Competitors

$33.84 +1.71 (+5.32%)

Closing price 04:00 PM Eastern

Extended Trading

$33.22 -0.63 (-1.85%)

As of 07:55 PM Eastern

Compare

ASMB vs. TRLV, CMPS, PRGO, ANIP, and AVLN

Should you buy Assembly Biosciences stock or one of its competitors? Assembly Biosciences's main competitors and comparable companies include Trulieve Cannabis (TRLV), Compass Pathways (CMPS), Perrigo (PRGO), ANI Pharmaceuticals (ANIP), and Avalyn Pharma (AVLN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Assembly Biosciences compare to Trulieve Cannabis?

Assembly Biosciences (NASDAQ:ASMB) and Trulieve Cannabis (NYSE:TRLV) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

19.9% of Assembly Biosciences shares are owned by institutional investors. 3.5% of Assembly Biosciences shares are owned by company insiders. Comparatively, 3.8% of Trulieve Cannabis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Assembly Biosciences currently has a consensus target price of $44.00, indicating a potential upside of 30.02%. Trulieve Cannabis has a consensus target price of $15.00, indicating a potential upside of 48.68%. Given Trulieve Cannabis' higher possible upside, analysts clearly believe Trulieve Cannabis is more favorable than Assembly Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assembly Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Trulieve Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Assembly Biosciences had 10 more articles in the media than Trulieve Cannabis. MarketBeat recorded 12 mentions for Assembly Biosciences and 2 mentions for Trulieve Cannabis. Assembly Biosciences' average media sentiment score of 0.63 beat Trulieve Cannabis' score of 0.00 indicating that Assembly Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Assembly Biosciences	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Trulieve Cannabis	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Trulieve Cannabis has lower revenue, but higher earnings than Assembly Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assembly Biosciences	$74.85M	7.19	-$6.12M	$1.02	33.18
Trulieve Cannabis	N/A	N/A	N/A	N/A	N/A

Trulieve Cannabis has a net margin of 0.00% compared to Assembly Biosciences' net margin of -0.06%. Trulieve Cannabis' return on equity of 0.00% beat Assembly Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assembly Biosciences	-0.06%	-0.02%	-0.02%
Trulieve Cannabis	N/A	N/A	N/A

Summary

Assembly Biosciences beats Trulieve Cannabis on 6 of the 11 factors compared between the two stocks.

How does Assembly Biosciences compare to Compass Pathways?

Assembly Biosciences (NASDAQ:ASMB) and Compass Pathways (NASDAQ:CMPS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, dividends and analyst recommendations.

Assembly Biosciences has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market. Comparatively, Compass Pathways has a beta of 2.5, meaning that its share price is 150% more volatile than the broader market.

19.9% of Assembly Biosciences shares are owned by institutional investors. Comparatively, 46.2% of Compass Pathways shares are owned by institutional investors. 3.5% of Assembly Biosciences shares are owned by company insiders. Comparatively, 2.8% of Compass Pathways shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Compass Pathways has a net margin of 0.00% compared to Assembly Biosciences' net margin of -0.06%. Assembly Biosciences' return on equity of -0.02% beat Compass Pathways' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assembly Biosciences	-0.06%	-0.02%	-0.02%
Compass Pathways	N/A	-49.63%	-13.08%

Assembly Biosciences presently has a consensus price target of $44.00, indicating a potential upside of 30.02%. Compass Pathways has a consensus price target of $23.36, indicating a potential upside of 66.72%. Given Compass Pathways' stronger consensus rating and higher possible upside, analysts plainly believe Compass Pathways is more favorable than Assembly Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assembly Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.88

Assembly Biosciences has higher revenue and earnings than Compass Pathways. Compass Pathways is trading at a lower price-to-earnings ratio than Assembly Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assembly Biosciences	$74.85M	7.19	-$6.12M	$1.02	33.18
Compass Pathways	N/A	N/A	-$287.86M	-$4.62	N/A

In the previous week, Assembly Biosciences had 8 more articles in the media than Compass Pathways. MarketBeat recorded 12 mentions for Assembly Biosciences and 4 mentions for Compass Pathways. Assembly Biosciences' average media sentiment score of 0.63 beat Compass Pathways' score of 0.26 indicating that Assembly Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Assembly Biosciences	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Compass Pathways	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Assembly Biosciences beats Compass Pathways on 9 of the 16 factors compared between the two stocks.

How does Assembly Biosciences compare to Perrigo?

Perrigo (NYSE:PRGO) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

In the previous week, Assembly Biosciences had 9 more articles in the media than Perrigo. MarketBeat recorded 12 mentions for Assembly Biosciences and 3 mentions for Perrigo. Assembly Biosciences' average media sentiment score of 0.63 beat Perrigo's score of 0.13 indicating that Assembly Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Perrigo	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Assembly Biosciences	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

95.9% of Perrigo shares are owned by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are owned by institutional investors. 0.4% of Perrigo shares are owned by company insiders. Comparatively, 3.5% of Assembly Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Perrigo presently has a consensus target price of $19.33, indicating a potential upside of 39.00%. Assembly Biosciences has a consensus target price of $44.00, indicating a potential upside of 30.02%. Given Perrigo's higher possible upside, analysts clearly believe Perrigo is more favorable than Assembly Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Assembly Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Assembly Biosciences has a net margin of -0.06% compared to Perrigo's net margin of -41.85%. Perrigo's return on equity of 11.25% beat Assembly Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Perrigo	-41.85%	11.25%	4.08%
Assembly Biosciences	-0.06%	-0.02%	-0.02%

Perrigo has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market. Comparatively, Assembly Biosciences has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market.

Assembly Biosciences has lower revenue, but higher earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Assembly Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perrigo	$4.25B	0.45	-$1.43B	-$12.51	N/A
Assembly Biosciences	$74.85M	7.19	-$6.12M	$1.02	33.18

Summary

Assembly Biosciences beats Perrigo on 11 of the 16 factors compared between the two stocks.

How does Assembly Biosciences compare to ANI Pharmaceuticals?

Assembly Biosciences (NASDAQ:ASMB) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability.

In the previous week, ANI Pharmaceuticals had 3 more articles in the media than Assembly Biosciences. MarketBeat recorded 15 mentions for ANI Pharmaceuticals and 12 mentions for Assembly Biosciences. Assembly Biosciences' average media sentiment score of 0.63 beat ANI Pharmaceuticals' score of 0.58 indicating that Assembly Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Assembly Biosciences	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
ANI Pharmaceuticals	6 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

19.9% of Assembly Biosciences shares are owned by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are owned by institutional investors. 3.5% of Assembly Biosciences shares are owned by company insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

ANI Pharmaceuticals has higher revenue and earnings than Assembly Biosciences. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Assembly Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assembly Biosciences	$74.85M	7.19	-$6.12M	$1.02	33.18
ANI Pharmaceuticals	$978.38M	1.83	$78.34M	$4.64	16.81

ANI Pharmaceuticals has a net margin of 11.07% compared to Assembly Biosciences' net margin of -0.06%. ANI Pharmaceuticals' return on equity of 27.37% beat Assembly Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assembly Biosciences	-0.06%	-0.02%	-0.02%
ANI Pharmaceuticals	11.07%	27.37%	10.47%

Assembly Biosciences has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market.

Assembly Biosciences currently has a consensus target price of $44.00, suggesting a potential upside of 30.02%. ANI Pharmaceuticals has a consensus target price of $105.83, suggesting a potential upside of 35.65%. Given ANI Pharmaceuticals' higher probable upside, analysts plainly believe ANI Pharmaceuticals is more favorable than Assembly Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assembly Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
ANI Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

ANI Pharmaceuticals beats Assembly Biosciences on 10 of the 16 factors compared between the two stocks.

How does Assembly Biosciences compare to Avalyn Pharma?

Avalyn Pharma (NASDAQ:AVLN) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

Avalyn Pharma has a net margin of 0.00% compared to Assembly Biosciences' net margin of -0.06%. Avalyn Pharma's return on equity of 0.00% beat Assembly Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalyn Pharma	N/A	N/A	N/A
Assembly Biosciences	-0.06%	-0.02%	-0.02%

19.9% of Assembly Biosciences shares are held by institutional investors. 3.5% of Assembly Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Avalyn Pharma currently has a consensus price target of $60.00, indicating a potential upside of 53.96%. Assembly Biosciences has a consensus price target of $44.00, indicating a potential upside of 30.02%. Given Avalyn Pharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Avalyn Pharma is more favorable than Assembly Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalyn Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
Assembly Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Avalyn Pharma has higher earnings, but lower revenue than Assembly Biosciences. Avalyn Pharma is trading at a lower price-to-earnings ratio than Assembly Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalyn Pharma	N/A	N/A	N/A	-$21.83	N/A
Assembly Biosciences	$74.85M	7.19	-$6.12M	$1.02	33.18

In the previous week, Assembly Biosciences had 5 more articles in the media than Avalyn Pharma. MarketBeat recorded 12 mentions for Assembly Biosciences and 7 mentions for Avalyn Pharma. Assembly Biosciences' average media sentiment score of 0.63 beat Avalyn Pharma's score of 0.36 indicating that Assembly Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalyn Pharma	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Assembly Biosciences	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Assembly Biosciences beats Avalyn Pharma on 8 of the 14 factors compared between the two stocks.

Get Assembly Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ASMB vs. The Competition

Export

Metric	Assembly Biosciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$537.82M	$12.50B	$7.31B	$12.85B
Dividend Yield	N/A	2.69%	2.56%	10.63%
P/E Ratio	33.18	779.76	269.48	24.25
Price / Sales	7.19	956.36	685.18	128.06
Price / Cash	N/A	15.16	28.88	38.50
Price / Book	2.60	10.66	11.36	6.46
Net Income	-$6.12M	$2.81B	$3.47B	$348.04M
7 Day Performance	25.06%	1.65%	2.41%	0.35%
1 Month Performance	26.22%	2.07%	4.29%	1.99%
1 Year Performance	34.18%	9.22%	29.18%	21.11%

Assembly Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ASMB Assembly Biosciences	3.0179 of 5 stars	$33.84 +5.3%	$44.00 +30.0%	+24.7%	$537.82M	$74.85M	33.18	100	News Coverage Earnings Report Analyst Forecast Analyst Revision Gap Up High Trading Volume
TRLV Trulieve Cannabis	3.6402 of 5 stars	$9.68 +6.2%	$15.00 +55.0%	N/A	$1.86B	N/A	N/A	5,000
CMPS Compass Pathways	2.5711 of 5 stars	$13.29 -6.5%	$23.36 +75.7%	+226.3%	$1.79B	N/A	N/A	120	Analyst Upgrade
PRGO Perrigo	3.6929 of 5 stars	$12.82 +1.0%	$19.33 +50.8%	-43.7%	$1.78B	$4.25B	N/A	8,100
ANIP ANI Pharmaceuticals	4.096 of 5 stars	$74.77 -0.5%	$105.83 +41.5%	-14.3%	$1.70B	$978.38M	16.11	600	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ASMB) was last updated on 8/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Assembly Biosciences (ASMB) Competitors

ASMB vs. TRLV, CMPS, PRGO, ANIP, and AVLN

How does Assembly Biosciences compare to Trulieve Cannabis?

Summary

How does Assembly Biosciences compare to Compass Pathways?

Summary

How does Assembly Biosciences compare to Perrigo?

Summary

How does Assembly Biosciences compare to ANI Pharmaceuticals?

Summary

How does Assembly Biosciences compare to Avalyn Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASMB vs. The Competition

Assembly Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Assembly Biosciences (ASMB) Competitors

ASMB vs. TRLV, CMPS, PRGO, ANIP, and AVLN

How does Assembly Biosciences compare to Trulieve Cannabis?

Do institutionals and insiders believe in ASMB or TRLV?

Do analysts recommend ASMB or TRLV?

Does the media favor ASMB or TRLV?

Which has higher earnings & valuation, ASMB or TRLV?

Is ASMB or TRLV more profitable?

Summary

How does Assembly Biosciences compare to Compass Pathways?

Which has more risk and volatility, ASMB or CMPS?

Do insiders and institutionals have more ownership in ASMB or CMPS?

Is ASMB or CMPS more profitable?

Do analysts recommend ASMB or CMPS?

Which has stronger valuation & earnings, ASMB or CMPS?

Does the media refer more to ASMB or CMPS?

Summary

How does Assembly Biosciences compare to Perrigo?

Does the media prefer PRGO or ASMB?

Do insiders & institutionals hold more shares of PRGO or ASMB?

Do analysts rate PRGO or ASMB?

Is PRGO or ASMB more profitable?

Which has more risk and volatility, PRGO or ASMB?

Which has higher valuation and earnings, PRGO or ASMB?

Summary

How does Assembly Biosciences compare to ANI Pharmaceuticals?

Does the media favor ASMB or ANIP?

Do insiders and institutionals have more ownership in ASMB or ANIP?

Which has better valuation & earnings, ASMB or ANIP?

Is ASMB or ANIP more profitable?

Which has more risk and volatility, ASMB or ANIP?

Do analysts prefer ASMB or ANIP?

Summary

How does Assembly Biosciences compare to Avalyn Pharma?

Is AVLN or ASMB more profitable?

Do insiders & institutionals hold more shares of AVLN or ASMB?

Do analysts prefer AVLN or ASMB?

Which has preferable valuation and earnings, AVLN or ASMB?

Does the media prefer AVLN or ASMB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASMB vs. The Competition

Assembly Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools